logo
Share SHARE
FONT-SIZE Plus   Neg

Sempra Energy's IEnova Prices IPO At Ps 34.00 Per Share - Quick Facts

Sempra Energy (SRE) announced that its subsidiary Infraestructura Energetica Nova, S.A.B. de C.V. or IEnova has priced its private offering of about 91.04 million shares of Class II, Single Series, common stock at an initial offering price of 34.00 Mexican pesosper share, or about US$2.75.

Simultaneously, IEnova also priced its initial public offering registered in Mexico of about 98.62 million shares of common stock at the same initial offering price. Settlement of the offerings is expected to occur on March 27, 2013.

The initial purchasers in the private offering and the underwriters in the Mexican public offering have been granted a 30-day option to purchase up to an additional 28.45 million shares of common stock at the initial offering price, less the underwriting discount, to cover overallotments, if any.

The aggregate shares of common stock to be sold in the offerings represent about 16.85 percent of IEnova's outstanding ownership interest, and approximately 18.9 percent of IEnova's outstanding ownership interest if the 30-day overallotment option is exercised in full.

The company estimates the net proceeds of the offerings to be about Ps.6.1 billion or US$496 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by IEnova, and prior to any exercise of the 30-day overallotment option.

IEnova expects to use the net proceeds of the offerings primarily for general corporate purposes, including the funding of its current investments and ongoing expansion plans.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This stock comes on our radar on the merit of its upbeat quarterly results. We believe the company has solid growth potential, as it expands through accretive acquisitions. In the next few-months, we see the stock touching new highs, and expect at least 20% upside from current levels. The month of February saw the FDA approve the second drug for Duchenne muscular dystrophy namely Emflaza. Now, let's take a look at the biotech stocks awaiting FDA decision in March. The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing....
comments powered by Disqus
Follow RTT